A malaria vaccine candidate has demonstrated efficacy above 75 percent in a large late-stage trial, a threshold global health officials have pursued for decades.
The trial, conducted across five countries in sub-Saharan Africa, enrolled more than 12,000 children — the population most vulnerable to the disease.
Why it matters
Malaria kills more than half a million people a year, most of them children under five. Existing vaccines offer partial protection; the new candidate could transform prevention.
What happens now
Regulators are reviewing the data under accelerated timelines. If approved, manufacturing partnerships aim to produce hundreds of millions of doses annually, with distribution prioritized for the highest-burden regions.
Reported with AI assistance from public sources; reviewed before publication. — Powered by Creytix.
Join the Conversation
Comments are moderated. Be kind.